{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:27:50Z","timestamp":1792196870632,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014653","name":"NIHR Manchester Biomedical Research Centre","doi-asserted-by":"publisher","award":["NIHR203308"],"award-info":[{"award-number":["NIHR203308"]}],"id":[{"id":"10.13039\/100014653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"NIHR Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.intimp.2025.115814","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T09:27:01Z","timestamp":1763371621000},"page":"115814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P1","title":["Anti-oxidative and anti-inflammatory effects of the phosphodiesterase 3\/4 inhibitor ensifentrine"],"prefix":"10.1016","volume":"168","author":[{"given":"Simon","family":"Lea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran","family":"Littolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajaluckcika","family":"Vijayacumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.intimp.2025.115814_bb0005","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1007\/s40265-021-01616-9","article-title":"Inhaled phosphodiesterase inhibitors for the treatment of chronic obstructive pulmonary disease","volume":"81","author":"Singh","year":"2021","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.intimp.2025.115814_bb0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1210\/er.2013-1053","article-title":"Clinical and molecular genetics of the phosphodiesterases (PDEs)","volume":"35","author":"Azevedo","year":"2014","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.intimp.2025.115814_bb0015","article-title":"cAMP-PDE signaling in COPD: review of cellular, molecular and clinical features","volume":"34","author":"Nourian","year":"2023","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.intimp.2025.115814_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2019.154739","article-title":"The modulatory effects of the PDE4 inhibitors CHF6001 and roflumilast in alveolar macrophages and lung tissue from COPD patients","volume":"123","author":"Lea","year":"2019","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.intimp.2025.115814_bb0025","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1124\/jpet.105.099192","volume":"318","author":"Boswell-Smith","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.intimp.2025.115814_bb0030","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/bcpt.12209","article-title":"Dual PDE3\/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases","volume":"114","author":"Abbott-Banner","year":"2014","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"11","key":"10.1016\/j.intimp.2025.115814_bb0035","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S2213-2600(18)30331-X","article-title":"Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial","volume":"6","author":"Rabe","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"9691","key":"10.1016\/j.intimp.2025.115814_bb0040","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(09)61255-1","article-title":"Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials","volume":"374","author":"Calverley","year":"2009","journal-title":"Lancet"},{"issue":"9971","key":"10.1016\/j.intimp.2025.115814_bb0045","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0140-6736(14)62410-7","article-title":"Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial","volume":"385","author":"Martinez","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.intimp.2025.115814_bb0050","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01074-2018","article-title":"The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD","volume":"52","author":"Singh","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.intimp.2025.115814_bb0055","first-page":"1","article-title":"Anti-inflammatory activity of Ensifentrine: a novel, selective dual inhibitor of phosphodiesterase 3 and phosphodiesterase 4","author":"Spina","year":"2025","journal-title":"Respiration"},{"issue":"9","key":"10.1016\/j.intimp.2025.115814_bb0060","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S2213-2600(13)70187-5","article-title":"Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials","volume":"1","author":"Franciosi","year":"2013","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.intimp.2025.115814_bb0065","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1164\/rccm.202306-0944OC","article-title":"Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for the treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials)","volume":"208","author":"Anzueto","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.intimp.2025.115814_bb0070","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1183\/09031936.06.00053805","article-title":"Oxidative stress and redox regulation of lung inflammation in COPD","volume":"28","author":"Rahman","year":"2006","journal-title":"Eur. Respir. J."},{"issue":"3","key":"10.1016\/j.intimp.2025.115814_bb0075","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1183\/09031936.05.00077604","article-title":"Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation","volume":"25","author":"Hodge","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"2","key":"10.1016\/j.intimp.2025.115814_bb0080","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1083\/jcb.144.2.281","article-title":"Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, \u22123, \u22126, \u22127, \u22128, and \u221210 in a caspase-9-dependent manner","volume":"144","author":"Slee","year":"1999","journal-title":"J. Cell Biol."},{"issue":"2","key":"10.1016\/j.intimp.2025.115814_bb0085","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1183\/09031936.05.00023704","article-title":"Correlation of lung surface area to apoptosis and proliferation in human emphysema","volume":"25","author":"Imai","year":"2005","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.115814_bb0090","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1465-9921-7-53","article-title":"Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema","volume":"7","author":"Demedts","year":"2006","journal-title":"Respir. Res."},{"issue":"14","key":"10.1016\/j.intimp.2025.115814_bb0095","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.7150\/ijbs.28050","article-title":"Nitric oxide prevents H(2)O(2)-induced apoptosis in SK-N-MC human neuroblastoma cells","volume":"14","author":"Yoo","year":"2018","journal-title":"Int. J. Biol. Sci."},{"issue":"3","key":"10.1016\/j.intimp.2025.115814_bb0100","first-page":"L323","article-title":"cGMP increases antioxidant function and attenuates oxidant cell death in mouse lung microvascular endothelial cells by a protein kinase G-dependent mechanism","volume":"299","author":"Stephens","year":"2010","journal-title":"Am. J. Phys. Lung Cell. Mol. Phys."},{"issue":"3","key":"10.1016\/j.intimp.2025.115814_bb0105","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00044-2022","article-title":"Differential responses of COPD macrophages to respiratory bacterial pathogens","volume":"8","author":"Lea","year":"2022","journal-title":"ERJ Open Res."},{"issue":"3","key":"10.1016\/j.intimp.2025.115814_bb0110","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00109-020-01873-3","article-title":"P38 MAPK and glucocorticoid receptor crosstalk in bronchial epithelial cells","volume":"98","author":"Lea","year":"2020","journal-title":"J. Mol. Med. (Berl.)"},{"issue":"3","key":"10.1016\/j.intimp.2025.115814_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41580-018-0089-8","article-title":"Regulation of apoptosis in health and disease: the balancing act of BCL-2 family proteins","volume":"20","author":"Singh","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"4","key":"10.1016\/j.intimp.2025.115814_bb0120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s41419-024-06632-7","article-title":"The broad impact of cell death genes on the human disease phenome","volume":"15","author":"Rich","year":"2024","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.intimp.2025.115814_bb0125","doi-asserted-by":"crossref","first-page":"430","DOI":"10.4049\/jimmunol.170.1.430","article-title":"Survival of mycobacterium tuberculosis in host macrophages involves resistance to apoptosis dependent upon induction of antiapoptotic Bcl-2 family member Mcl-1","volume":"170","author":"Sly","year":"2003","journal-title":"J. Immunol."},{"issue":"20","key":"10.1016\/j.intimp.2025.115814_bb0130","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.1111\/febs.16136","article-title":"Understanding MCL1: from cellular function and regulation to pharmacological inhibition","volume":"289","author":"Sancho","year":"2022","journal-title":"FEBS J."},{"issue":"6","key":"10.1016\/j.intimp.2025.115814_bb0135","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1091\/mbc.e12-10-0747","article-title":"Regulation of apoptosis by Bcl-2 cysteine oxidation in human lung epithelial cells","volume":"24","author":"Luanpitpong","year":"2013","journal-title":"Mol. Biol. Cell"},{"issue":"21","key":"10.1016\/j.intimp.2025.115814_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cells13211750","article-title":"Dual inhibition of phosphodiesterase 3 and 4 enzymes by Ensifentrine protects against MRSA-induced lung endothelial and epithelial dysfunction","volume":"13","author":"Al Matni","year":"2024","journal-title":"Cells"},{"issue":"4","key":"10.1016\/j.intimp.2025.115814_bb0145","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/thx.2004.027946","article-title":"Oxidative stress and airway inflammation in severe exacerbations of COPD","volume":"60","author":"Drost","year":"2005","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.intimp.2025.115814_bb0150","first-page":"27","article-title":"Oxidative stress in chronic obstructive pulmonary disease: a lung and systemic process","volume":"20","author":"van Eeden","year":"2013","journal-title":"Can. Respir. J."},{"issue":"1","key":"10.1016\/j.intimp.2025.115814_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0022-3565(24)29537-9","article-title":"Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro","volume":"297","author":"Hatzelmann","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115814_bb0160","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1124\/jpet.114.220541","article-title":"CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration","volume":"352","author":"Moretto","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2025.115814_bb0165","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.110.173690","article-title":"GSK256066, an exceptionally high-affinity and selective inhibitor of phosphodiesterase 4 suitable for administration by inhalation: in vitro, kinetic, and in vivo characterization","volume":"337","author":"Tralau-Stewart","year":"2011","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2025.115814_bb0170","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/jpet.120.000080","article-title":"The phosphodiesterase inhibitor Ensifentrine reduces production of proinflammatory mediators in well differentiated bronchial epithelial cells by inhibiting PDE4","volume":"375","author":"Turner","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.intimp.2025.115814_bb0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s12931-016-0325-8","article-title":"Additive anti-inflammatory effects of corticosteroids and phosphodiesterase-4 inhibitors in COPD CD8 cells","volume":"17","author":"Grundy","year":"2016","journal-title":"Respir. Res."},{"key":"10.1016\/j.intimp.2025.115814_bb0180","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2018.06.007","article-title":"Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients","volume":"113","author":"Southworth","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2025.115814_bb0185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2020.00259","article-title":"Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases","volume":"11","author":"Phillips","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.intimp.2025.115814_bb0190","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.740803","article-title":"Tanimilast, a novel inhaled Pde4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease","volume":"12","author":"Facchinetti","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925018028?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576925018028?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T19:40:47Z","timestamp":1781898047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576925018028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"alternative-id":["S1567576925018028"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115814","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-oxidative and anti-inflammatory effects of the phosphodiesterase 3\/4 inhibitor ensifentrine","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2025.115814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115814"}}